[EN] COMPOSITIONS AND METHODS RELATED TO ANTI-CD19 ANTIBODY DRUG CONJUGATES<br/>[FR] COMPOSITIONS ET MÉTHODES ASSOCIÉES À DES CONJUGUÉS ANTICORPS ANTI-CD19-MÉDICAMENTS
申请人:LEGOCHEM BIOSCIENCES INC
公开号:WO2017051249A1
公开(公告)日:2017-03-30
In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-CD 19 antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
[EN] COMPOUNDS AND METHODS FOR THE IDENTIFICATION OF HISTONE DEMETHYLASE INTERACTING MOLECULES AND FOR THE PURIFICATION OF HISTONE DEMETHYLASE PROTEINS<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR IDENTIFIER DES MOLÉCULES AYANT UNE INTERACTION AVEC LES HISTONES DÉMÉTHYLASES ET POUR PURIFIER DES PROTÉINES D'HISTONE DÉMÉTHYLASE
申请人:CELLZOME AG
公开号:WO2012150042A1
公开(公告)日:2012-11-08
The present invention relates to immobilization compounds, immobilization products and preparations thereof as well as methods and uses for the identification of histone demethylase interacting compounds or for the purification or identification of histone demethylase proteins.
Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.
Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments
申请人:Auckland Uniservices Limited
公开号:US07989451B2
公开(公告)日:2011-08-02
The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula I
and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.
The present disclosure provides conjugate structures and compound structures used to produce these conjugates. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.